GlycoMimetics Inc (GLYC)
0.3898
-0.02
(-4.93%)
USD |
NASDAQ |
Nov 05, 16:00
0.3898
0.00 (0.00%)
After-Hours: 18:55
GlycoMimetics Enterprise Value: 4.052M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 4.052M |
| November 01, 2024 | 2.286M |
| October 31, 2024 | 3.852M |
| October 30, 2024 | 7.051M |
| October 29, 2024 | 9.211M |
| October 28, 2024 | -11.54M |
| October 25, 2024 | -11.23M |
| October 24, 2024 | -11.18M |
| October 23, 2024 | -10.94M |
| October 22, 2024 | -11.75M |
| October 21, 2024 | -12.07M |
| October 18, 2024 | -12.17M |
| October 17, 2024 | -12.17M |
| October 16, 2024 | -12.27M |
| October 15, 2024 | -12.56M |
| October 14, 2024 | -12.80M |
| October 11, 2024 | -12.71M |
| October 10, 2024 | -13.08M |
| October 09, 2024 | -13.13M |
| October 08, 2024 | -12.53M |
| October 07, 2024 | -12.33M |
| October 04, 2024 | -12.08M |
| October 03, 2024 | -12.06M |
| October 02, 2024 | -12.46M |
| October 01, 2024 | -11.69M |
| Date | Value |
|---|---|
| September 30, 2024 | -11.49M |
| September 27, 2024 | -11.62M |
| September 26, 2024 | -11.39M |
| September 25, 2024 | -12.10M |
| September 24, 2024 | -11.78M |
| September 23, 2024 | -11.78M |
| September 20, 2024 | -11.76M |
| September 19, 2024 | -11.42M |
| September 18, 2024 | -11.81M |
| September 17, 2024 | -11.75M |
| September 16, 2024 | -11.93M |
| September 13, 2024 | -11.42M |
| September 12, 2024 | -11.81M |
| September 11, 2024 | -11.91M |
| September 10, 2024 | -12.15M |
| September 09, 2024 | -11.86M |
| September 06, 2024 | -12.26M |
| September 05, 2024 | -11.77M |
| September 04, 2024 | -12.02M |
| September 03, 2024 | -11.42M |
| August 30, 2024 | -11.02M |
| August 29, 2024 | -11.22M |
| August 28, 2024 | -11.42M |
| August 27, 2024 | -10.78M |
| August 26, 2024 | -10.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-78.44M
Minimum
Mar 18 2020
182.94M
Maximum
Jan 23 2024
21.38M
Average
9.211M
Median
Oct 29 2024
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 12.24B |
| Arbutus Biopharma Corp | 586.71M |
| FibroGen Inc | 6.090M |
| Cidara Therapeutics Inc | -72.66M |
| Cue Biopharma Inc | 65.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.10M |
| Total Expenses (Quarterly) | 10.36M |
| EPS Diluted (Quarterly) | -0.16 |
| Earnings Yield | -156.5% |
| Normalized Earnings Yield | -148.79 |